Latest in Blockbuster Obesity

Sort by

3 items

Hikma races to launch generic versions of blockbuster obesity drugs

Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year
Financial Times - 1d
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance
ABC News - 4d
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
The New York Times - 4d

Hikma races to launch generic versions of blockbuster obesity drugs